From CNBC:

Hims & Hers Health had its best day on the stock market after quarterly results beat estimates, projecting its first year of profitability in 2024. Shares rose 31% to $13.43, up over 50% for the year. Revenue hit $246.6 million, exceeding analysts’ $246 million forecast. For 2025, they anticipate over $100 million in revenue from new specialties such as mental health. CEO Dudum is positive about the company’s future growth.

Hims & Hers forecasts adjusted earnings of $22 million to $27 million for the first quarter, surpassing analysts’ $14 million estimate. Revenue grew 47% to $246.6 million in the fourth quarter, well above the expected $246 million. The CEO highlighted strong performance in mental health and newer specialties, looking to deliver over $100 million in revenue from each category in 2025.

Deutsche Bank analysts raised their price target for Hims & Hers from $8 to $14, maintaining a hold rating. The company released strong 2024 guidance, surprising investors. Jefferies analysts recommended buying the shares due to strong revenue, profitability, and guidance, comparing the results to a satisfying Thanksgiving dinner. Revenue for 2025 is expected to surpass $1.17 billion.



Read more at CNBC:: Hims & Hers (HIMS) Q4 earnings report